Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7722MR)

This product GTTS-WQ7722MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7722MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7467MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ8813MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ4232MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ14627MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ1292MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ2740MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ15396MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ5025MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA c4G7-N
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW